Format

Send to

Choose Destination
Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Author information

1
University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany claus.vogelmeier@med.uni-marburg.de.
2
These authors contributed equally to the manuscript.
3
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
4
New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.
5
University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX, USA.
6
National Heart and Lung Institute, Imperial College, London, UK.
7
McGill University Health Centre, McGill University, Montreal, Canada.
8
Brigham and Women's Hospital, Boston, MA, USA.
9
State Key Lab for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
10
University of Leuven, Leuven, Belgium.
11
University of Modena and Reggio Emilia, Modena, Italy.
12
Flinders University Faculty of Medicine, Bedford Park, Australia.
13
Royal Devon and Exeter Hospital, Exeter, UK.
14
Universidad de la República, Hospital Maciel, Montevideo, Uruguay.
15
Hokkaido University School of Medicine, Sapporo, Japan.
16
Hôpital Cochin (APHP), University Paris Descartes, Paris, France.
17
Thorax Institute, Hospital Clinic Universitat de Barcelona, Barcelona, Spain.
18
St Paul's Hospital, University of British Columbia, Vancouver, Canada.
19
University of Manchester, Manchester, UK.
20
University Hospital, Birmingham, UK.
21
Hospital Clínic, Universitat de Barcelona, Ciberes, Barcelona, Spain.

Abstract

This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.

PMID:
28182564
DOI:
10.1183/13993003.00214-2017
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center